Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis

  title={Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis},
  author={J-Y. Reginster and J-M. Kaufman and Stefan Goemaere and J. P. Devogelaer and C. Laurent Benhamou and Dieter Felsenberg and Manuel D{\'i}az-Curiel and M-L. Brandi and Janusz E Badurski and John Dennis Wark and Ad{\'a}m Tam{\'a}s Balogh and Olivier Bruy{\`e}re and Christian Roux},
  booktitle={Osteoporosis International},
In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term. Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. We… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 37 extracted citations


Publications referenced by this paper.
Showing 1-10 of 24 references

Five-year denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the FREEDOM trial extension. OC24

  • S Papapoulos, Z Man, D Mellstrom
  • Osteoporos Int 22(suppl
  • 2011
2 Excerpts

The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Abstract 1070

  • DM Black, I Reid, J Cauley
  • J Bone Miner Res
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…